Moreover, a decrease of DKK1 serum level in patients with advanced prostate cancer has been reported to be associated with occurrence of osteoblastic lesions which suggests that DKK1 inhibition in PC3c cells may contribute to the osteoblastic phenotype induced by these cells [12]. Here, DKK1 is linked to prostate carcinoma.